Royalty Pharma
RPRX
$0.22 (-0.76%)
1D
1W
3M
1Y
5Y
ALL
Royalty Pharma plc is engaged in investing in late stage biopharmaceutical products. The Company invests in academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The Company’s portfolio of pharmaceutical investment includes investments in commercial products and development-stage product candidates. Its portfolio investments include AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko, Trikafta and OXLUMO.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
Zacks Investment Research • 2 days ago • RPRX
Insights Into Royalty Pharma (RPRX) Q1: Wall Street Projections for Key MetricsZacks Investment Research • 6 days ago • RPRX
Royalty Pharma (RPRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseGlobeNewsWire • 19 days ago • RPRX
Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024GlobeNewsWire • 21 days ago • RPRX
Royalty Pharma Declares Second Quarter 2024 DividendInvestorPlace • 26 days ago • RPRX
3 Pharma Stocks to Sell in April Before They Crash & BurnCharts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.